Saunders Luke J, Medeiros Felipe A, Weinreb Robert N, Zangwill Linda M
Expert Rev Ophthalmol. 2016;11(3):227-234. doi: 10.1080/17469899.2016.1180246. Epub 2016 May 13.
Clinically important rates of glaucoma progression (worsening) are ones that put a patient at risk of future functional impairment or reduction of vision-related quality of life. Rates of progression can be evaluated through measuring structural or functional changes of the optic nerve. Most treated eyes do not progress at rates that will lead to future visual impairment, but there are a significant proportion (3-17%) of eyes, that are at risk of impairment even under clinical care. While very fast rates of progression (e.g. MD progression of -1.5 dB/year) are generally problematic, much slower rates also may be deleterious for young patients, particularly those diagnosed with late disease. As a result, it is important to consider life expectancy, disease severity and vision-related quality of life based treatment targets to estimate future prognosis when evaluating whether a rate of glaucoma progression can be clinically relevant.
具有临床意义的青光眼进展(恶化)速率是指会使患者面临未来功能损害或视力相关生活质量下降风险的速率。进展速率可通过测量视神经的结构或功能变化来评估。大多数接受治疗的眼睛不会以导致未来视力损害的速率进展,但仍有相当比例(3% - 17%)的眼睛即使在临床护理下也有受损风险。虽然非常快的进展速率(例如平均偏差每年进展 -1.5 dB)通常存在问题,但对于年轻患者,尤其是那些被诊断为晚期疾病的患者,慢得多的速率也可能有害。因此,在评估青光眼进展速率是否具有临床相关性时,考虑基于预期寿命、疾病严重程度和视力相关生活质量的治疗目标以估计未来预后非常重要。